8-KLeadership Changes

BIOGEN INC. 8-K Report, Executive Changes (Jun 21, 2016)

Filed June 21, 2016For Securities:BIIB

Summary

This 8-K filing from Biogen Inc. announces a significant leadership change within its Pharmaceutical Operations and Technology division. Effective July 1, 2016, John Cox will depart from his role as Executive Vice President to assume the CEO position of a new entity being formed as part of Biogen's planned spin-off of its hemophilia business. This move is a strategic step in preparing for the separation and launch of the independent hemophilia-focused company. While Mr. Cox's departure from his current operational role is effective, he will remain employed by Biogen until the spin-off is finalized. During this transition period, his focus will be on the critical planning and execution required for the successful launch of the new hemophilia company. Investors should view this as a key development in Biogen's ongoing strategy to separate its hemophilia assets and potentially unlock value for shareholders, while allowing Biogen to concentrate on its core neuroscience portfolio.

Key Highlights

  • 1John Cox is stepping down as Executive Vice President, Pharmaceutical Operations and Technology, effective July 1, 2016.
  • 2Mr. Cox will become CEO of a new company created from Biogen's proposed hemophilia business spin-off.
  • 3Cox will continue employment with Biogen until the spin-off is completed.
  • 4His focus during the transition will be on planning the launch of the new hemophilia company.
  • 5This change is directly tied to Biogen's strategic decision to spin off its hemophilia business.

Frequently Asked Questions

John Cox is stepping down to take on the CEO role for the new company that will be created from Biogen's proposed spin-off of its hemophilia business.

No, Mr. Cox will continue to be employed by Biogen until the hemophilia business spin-off is completed. He will be focused on planning for the launch of the new company during this period.

This announcement is a concrete step in Biogen's plan to separate its hemophilia business. It signals progress in the spin-off process, which could lead to a more focused Biogen operating in its core neuroscience areas and a separate entity dedicated to hemophilia treatments.

The new company will be entirely focused on Biogen's hemophilia business, which is being spun off. John Cox's leadership as CEO will be dedicated to its successful launch and future operations.